Form 4: CalciMedica insider acquires 1,000 shares at $1.85

Rhea-AI Filing Summary

On 07/01/2025, CalciMedica, Inc. (ticker CALC) filed a Form 4 disclosing that its Chief Scientific Officer, Kenneth A. Stauderman, executed a single open-market purchase marked with transaction code “P.” The transaction, carried out through his spouse’s account, involved 1,000 shares of CalciMedica common stock at a price of $1.85 per share, for an aggregate cost of roughly $1,850. Following the purchase, Stauderman reports indirect beneficial ownership of the 1,000 newly acquired shares and direct ownership of 11,944 shares. No derivative transactions were reported, and the filing is made solely by one reporting person. The form does not indicate use of a Rule 10b5-1 plan.

Insights

Securities Analyst

TL;DR: Insignificant insider buy—1,000 CALC shares at $1.85; signals limited confidence, immaterial to valuation.

The disclosed purchase is very small—about $1.9 k—relative to CalciMedica’s daily trading volume and market capitalization. While insider buying can be interpreted as a positive signal, the size here is too minor to materially influence investor sentiment or fundamentals. The transaction increases total insider ownership only fractionally (rough insider stake data not provided). With no accompanying sales, it neither strengthens nor weakens governance outlook. Accordingly, I view the filing as informational but not impactful for valuation or trading strategy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stauderman Kenneth A.

(Last) (First) (Middle)

CALCIMEDICA, INC.

505 COAST S. BLVD. #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		P		1,000	A	$1.85	1,000	I	By Spouse
Common Stock								11,944	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Dunn, Esq., Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CalciMedica (CALC) report on 07/02/2025?

A Form 4 showed the CSO purchased 1,000 shares of common stock on 07/01/2025 at $1.85 per share.

How many CALC shares does Kenneth A. Stauderman now own?

After the transaction he reports 11,944 shares held directly and 1,000 shares held indirectly through his spouse.

Was the transaction executed under a Rule 10b5-1 plan?

No. The filing does not check the 10b5-1 box, indicating it was not made under a pre-arranged trading plan.

Did the Form 4 disclose any derivative security activity?

No derivative securities were acquired or disposed of; Table II remains blank.